Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus

International Journal of Rheumatic DiseasesVolume 26, Issue 7 p. 1399-1402 CORRESPONDENCE Safety, efficacy and pharmacokinetics of low-dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus Xin Guan, Xin Guan orcid.org/0000-0002-7385-4491 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, ChinaSearch for more papers by this authorZerui Zhao, Zerui Zhao orcid.org/0000-0002-9364-5590 Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, ChinaSearch for more papers by this authorGuangtao Xia, Guangtao Xia orcid.org/0000-0001-5975-3785 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, ChinaSearch for more papers by this authorMiaomiao Xin, Miaomiao Xin orcid.org/0000-0003-1666-4402 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, ChinaSearch for more papers by this authorQingrui Yang, Qingrui Yang orcid.org/0000-0001-8298-2148 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, ChinaSearch for more papers by this authorHongling Sun, Hongling Sun orcid.org/0000-0002-4224-4244 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, ChinaSearch for more papers by this authorMin Fu, Corresponding Author Min Fu [email protected] orcid.org/0000-0002-7659-4074 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China Correspondence Min Fu, Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), No. 324, Jingwuweiqi Road, Jinan, Shandong 250021, China. Email: [email protected]Search for more papers by this author Xin Guan, Xin Guan orcid.org/0000-0002-7385-4491 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, ChinaSearch for more papers by this authorZerui Zhao, Zerui Zhao orcid.org/0000-0002-9364-5590 Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, ChinaSearch for more papers by this authorGuangtao Xia, Guangtao Xia orcid.org/0000-0001-5975-3785 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, ChinaSearch for more papers by this authorMiaomiao Xin, Miaomiao Xin orcid.org/0000-0003-1666-4402 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, ChinaSearch for more papers by this authorQingrui Yang, Qingrui Yang orcid.org/0000-0001-8298-2148 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, ChinaSearch for more papers by this authorHongling Sun, Hongling Sun orcid.org/0000-0002-4224-4244 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, ChinaSearch for more papers by this authorMin Fu, Corresponding Author Min Fu [email protected] orcid.org/0000-0002-7659-4074 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China Correspondence Min Fu, Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), No. 324, Jingwuweiqi Road, Jinan, Shandong 250021, China. Email: [email protected]Search for more papers by this author First published: 19 February 2023 https://doi.org/10.1111/1756-185X.14613Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, f or the treatment of systemic lupus erythematosus. Drugs Today (Barc). 2022; 58(1): 23-32. 2Zhao Q, Chen X, Hou Y, et al. Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of RCT-18 in Chinese patients with systemic lupus erythematosus. J Clin Pharmacol. 2016; 56: 948-959. 3Lazaro D. Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment. Drugs Aging. 2007; 24(9): 701-715. 4Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29(2): 288-291. 5Jesus D, Larosa M, Henriques C, et al. Systemic lupus erythematosus disease activity score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. Ann Rheum Dis. 2021; 80(12): 1568-1574. 6Sun L, Shen Q, Gong Y, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial. Lupus. 2022; 31(8): 998-1006. 7Apostolopoulos D, Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2017; 56(suppl_1): i114-i122. 8Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003; 110(7): 1321-1326. 9Dutta S, Breslin A, Ahmad Y, eds. Tacrolimus in rheumatoid arthritis: a safe and effective DMARD. Annual Meeting of the British-Society-Rheumatology/Spring Meeting of; 2010. 10Chu VT, Enghard P, Schürer S, Steinhauser G, Berek C. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2010; 60(7): 2083-2093. 11Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014; 10(6): 365-373. Volume26, Issue7July 2023Pages 1399-1402 ReferencesRelatedInformation